Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide (Q34132767)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide |
scientific article |
Statements
1 reference
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide (English)
1 reference
Mei-Yin C Polley
1 reference
Kathleen R Lamborn
1 reference
Susan M Chang
1 reference
Nicholas Butowski
1 reference
Jennifer L Clarke
1 reference
Michael Prados
1 reference
21 December 2009
1 reference
1 reference
Identifiers
1 reference